Trial Profile
Phase II trial of lexibulin as second-line therapy in patients with mesothelioma who have failed pemetrexed treatment
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2008
Price :
$35
*
At a glance
- Drugs Lexibulin (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- Sponsors YM BioSciences Australia
- 19 Mar 2008 New trial record.